ArticleNeurology international2025

Continuation, Resumption, and Withdrawal Rates of CGRP-mAb Treatment for Migraine Under Real-World Clinical Conditions in Which Patients Are Free to Choose Own Treatment.

Takafumi Tanei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.